Forest Savella’s Launch For Fibromyalgia: Many Sales Forces, Single Claim
Executive Summary
Forest's promotional messaging for the launch of its fibromyalgia drug Savella (milnacipran) has a somewhat unusual emphasis - the product's limited utility
You may also be interested in...
Forest Continues To Bank On Growth Of its Savella Medication for Fibromyalgia
With the only drug indicated solely for fibromyalgia, Forest expects Savella to help offset declining sales from its Lexapro antidepressant.
Offsetting The Pain: Forest Pushes Savella To Dampen A Lexapro Sales Slide
Forest's Savella is gaining 1,200 to 1,300 new prescribers per week and now has a 3.5 percent share of the market for fibromyalgia treatments
Fibromyalgia Market Snapshot: Forest Delays Savella Launch
Forest is delaying the launch of its recently approved fibromyalgia drug Savella (milnacipran) until at least May, when FDA is expected to okay a tablet-color change. Analysts do not anticipate the move will impact the drug's long-term sales when it joins Pfizer's Lyrica and Lilly's Cymbalta on the market